NCT04833205 is a Phase 2 clinical trial of Nimotuzumab in Leptomeningeal Metastasis, sponsored by Hui Bu.

Who is sponsoring NCT04833205?

NCT04833205 is sponsored by Hui Bu.

What drugs are being tested in NCT04833205?

Interventions in NCT04833205: Nimotuzumab.

What condition does NCT04833205 study?

NCT04833205 studies Leptomeningeal Metastasis, Lung Cancer.

Is NCT04833205 still recruiting?

NCT04833205 is currently status unknown. Last updated 20 April 2021.

Last reviewed 2021-04-20 · How we verify

NCT04833205

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Status unknown Phase 2 Last updated 20 April 2021

What this trial tests

Phase 2 trial testing Nimotuzumab in Leptomeningeal Metastasis in 30 participants. Status unknown.

Timeline

19 April 2021

Primary endpoint
19 April 2022

19 April 2023

Quick facts

Lead sponsor	Hui Bu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	19 April 2021
Primary completion	19 April 2022
Estimated completion	19 April 2023
Sites	2 locations across China

Drugs / interventions tested

Nimotuzumab — full drug profile →

Conditions studied

Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

Hui Bu — full company profile →

Who can join

18 and older, any sex, with Leptomeningeal Metastasis or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Leptomeningeal Metastases: New Opportunities in the Modern Era.
Wilcox JA, Li MJ, Boire AA. · · 2022 · cited 25× · PMID 35790709 · DOI 10.1007/s13311-022-01261-4
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases.
Wilcox JA, Boire AA. · · 2023 · cited 17× · PMID 36474108 · DOI 10.1007/s40263-022-00975-5
Novel Therapeutic Approaches in Neoplastic Meningitis.
Khosla AA, Saxena S, Ozair A, Venur VA, et al · · 2022 · cited 8× · PMID 36612116 · DOI 10.3390/cancers15010119

Verify or expand the search:

Other trials of Nimotuzumab

Trials testing the same drug.

NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
NCT07457528 — Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · Phase 2 · recruiting
NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
NCT07277452 — Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline R · Phase 2 · not yet recruiting

Other recruiting trials for Leptomeningeal Metastasis

Currently open trials in the same condition.

NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
NCT06296745 — Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. · Phase 2 · recruiting
NCT07098806 — Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases · Phase 1 · recruiting
NCT06984523 — Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomening · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04833205 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hui Bu
Last refreshed: 20 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04833205.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing